Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Ponatinib
CAS 943319-70-8
Panatinib is an anticancer drug. In December 2012, it was approved by FDA to be used in the treatment of adult chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph + acute lymphoblastic leukemia (all). It is mainly used to treat patients who have no effect on dasatinib or nilotinib treatment, or who cannot tolerate dasatinib or nilotinib, and patients who are not suitable for follow-up treatment of imatinib. It can also be used to treat patients with gene mutation ("T315I mutation"), which makes patients resistant to imatinib, dasatinib or nilotinib. It is also used to treat CML and Ph + all in adults who have not used other TKIs. At present, it is the only available drug for BCR ABL kinase T315I mutation.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
